Introduction
Use of endoscopic ultrasound (EUS) in children is increasing but remains limited due
to the lack of trained pediatric gastroenterologists and advanced centers with expertise
in pediatric EUS [1]
[2]. The indications for EUS have been expanding in adults, many of which have now been
explored in children. The prevalence of pediatric digestive diseases is increasing.
EUS is an emerging tool and valuable in diagnosing and managing a varied range of
childhood illnesses, pancreaticobiliary diseases, eosinophilic esophagitis, inflammatory
bowel disease, congenital anomalies, and submucosal lesions [3]
[4]. Its diagnostic competence with fine-needle aspiration is proven to be safe and
technically successful in pediatric patients [5]. EUS is an accurate tool when compared to conventional endoscopy as to whether endoscopic
or surgical resection is needed for benign/ malignant lesions [6]. The diagnostic role of EUS might influence outcomes and bring about changes in
management. Although various pediatric studies have been performed [7]
[8]
[9]
[10], the role of EUS and its utility in advanced illnesses is little explored. The purpose
of this study was to look for the indications of EUS, meaningful impact, and the occurrence
of complications among children with predominant upper gastrointestinal etiology.
Patients and methods
This was a retrospective analysis of prospectively collected data from patients who
underwent EUS procedures performed between January 2018 and December 2020. This study
was conducted in accordance with Good Clinical Practice and in a manner to conform
with the Helsinki Declaration of 1975 and its later amendments concerning human rights.
The study protocol was approved by the institutional ethics committee (Approval number:
IEC/OA-24/20), and waiver of consent was obtained. Indications, findings, interventions
and complications of the procedures in these patients was assessed. All children had
been evaluated clinically with relevant blood and radiological investigations (ultrasonography/contrast-enhanced
computed tomography abdomen/MRCP) prior to EUS. In majority of the cases an upper
gastrointestinal endoscopy was already done prior to EUS.
Antibiotic prophylaxis was not administered before diagnostic EUS. For interventional
EUS, amoxicillin and clavulanic acid were used according to the weight of the patient.
The type of anesthesia was chosen based on the patient’s age, weight, and the procedure
of interest. Total intravenous anesthesia (TIVA) and general anesthesia (GA) were
used in this patient population. All procedures were performed by an experienced endosonographer
(AD). Diagnostic EUS was performed using a combination of the radial and curvilinear
echoendoscope. EUS-FNA, where indicated, and interventional EUS were performed using
a curvilinear echoendoscope (GF-UCT 180, Olympus Corp, Japan). Procedures had been
performed with patients in the left lateral decubitus position. A complete examination
of the organ of interest was performed with standard maneuvers. Hepatopancreatobiliary
evaluation was done from the stomach and duodenum. A mediastinal examination was done
from the esophagus. Evaluation of subepithelial lesions was performed using a radial
echoendoscope and switched to the curvilinear scope if FNA was required. The maneuvers
for curvilinear EUS were done as previously described [11]
[12]. EUS-FNA/B was performed using 22 or 25 gauge FNA/B needles (EchoTip ProCore Cook
Medical, Bloomington, Indiana, United States; Expect, Boston Scientific Co., Natick,
Massachusetts, United States; Acquire 22 G FNB needle (Boston Scientific Co., Natick,
Massachusetts, United States). Color Doppler was used to identify the best position
for puncture, avoiding interposing blood vessels between the target lesion. FNA was
performed using the slow pull technique. Two or three needle passes were made for
solid lesions. A macroscopic on-site evaluation was used for assessing tissue adequacy
[13]. For cystic lesions, a single pass was carried out with near-total aspiration of
the fluid content to decrease the risk of infection. Interventional procedures were
performed using the 19 gauge FNA needle. Interventional procedures included drainage
of pancreatic fluid collections and biliary drainage. Transmural pancreatic pseudocyst
or walled off necrosis drainage was performed by EUS guided placement of a lumen-apposing
metal stent (LAMS) (15–20 mm: Hot LAMS; Boston Scientific, Marlborough, Massachusetts,
United States) or a biflanged metal stent (30 mm length, 10.5 Fr, Niti-S Nagi stent,
Taewoong Medical Co., Seoul, Korea). EUS guided rendezvous technique (EUS-RV) was
also performed as previously described [14]. A meaningful clinical impact was observed when a definitive diagnosis was attained
that altered the future course of management.
Safety
Predefined procedural complications were classified as defined by the ASGE lexicon
criterion [15]. The timeframe for assessing these was mainly during the procedure, and immediately
post-procedure up to 4 hours and/or observations from referring physicians afterward.
Patients who had hospitalization had an additional assessment at 24 and 48 hours.
Statistics
Quantitative data was entered in Microsoft Excel (Office 2016 Professional for Windows;
Microsoft). The statistical analysis was performed using IBM Statistical Package for
the Social Sciences (SPSS) Statistics for Windows [version 23.0, Professional] (IBM
Corp, Armonk, New York, United States). Missing data were analyzed using available
case analysis. For categorical variables, frequency and percentage are given. For
continuous variables, descriptive statistics was used (mean with standard deviation).
Results
Eighty-five patients (70.5 % male; mean [SD] age of 12.1 years [3.9]) underwent EUS
procedures, and seven of them underwent a repeat EUS at follow-up. EUS was successfully
completed in all patients. The major indication for EUS was abdominal pain unexplained
by other imaging techniques in 45 (52.9 %) and jaundice/cholangitis in 15 patients
(17.6 %) ([Table 1]). GA was used in 12 (13 %) and TIVA in 80 patients (87 %). As per ASA classification,
73 patients were classified as ASA I, 12 patients were classified as ASA II. The mean
(SD) procedural time for diagnostic EUS was 15.4 minutes (3.1). The total time of
EUS-RV was 35 minutes, while EUS-guided cystogastrostomy done in four patients took
on an average of 26 minutes. The commonest diagnostic findings were choledocholithiasis
in 21 (24.7 %) and cholelithiasis in 12 patients (14.1 %) ([Table 2]). FNB was performed in 17 cases (20 %), mainly in patients with enlarged lymph nodes,
subepithelial gastric lesions, and pancreatic masses. Tuberculosis was the commonest
diagnosis in patients with enlarged lymph nodes. Among patients evaluated for unexplained
abdominal pain and recurrent acute pancreatitis, 13 patients were diagnosed to have
features of chronic pancreatitis, while 2 patients were diagnosed to have a pancreatic
divisum. Patients with equivocal changes of chronic pancreatitis on the initial EUS
underwent a repeat scan after three months, and two of 85 cases (2.3 %) had progressive
disease with parenchymal calcification. EUS was considered normal in 16 patients (18.8 %).
Overall, EUS had a meaningful impact on the subsequent clinical management in 69 cases
(81.2 %).
Table 1
Baseline characteristics.
|
Variable
|
N (%)
|
|
No. of patients
|
85 (100)
|
|
Age at time of EUS, mean (SD), y
|
12.1 (3.9)
|
|
Male
|
60 (70.5)
|
|
Indication for procedure[1]
|
|
|
45 (52.9)
|
|
|
15 (17.6)
|
|
|
12 (14.1)
|
|
|
8 (9.4)
|
|
|
5 (5.8)
|
|
|
5 (5.8)
|
|
|
4 (4.7)
|
|
|
4 (4.7)
|
|
Hemoglobin (g/dL)
|
12.9 (2.3)
|
|
Leukocytes (109 × L)
|
6.9 (3.1)
|
|
Platelets (109 × L)
|
214 (56.5)
|
|
Amylase (U/L)
|
125 (29.6)
|
|
Lipase (U/L)
|
145 (38.5)
|
|
Total bilirubin (mg/dL)
|
1.1 (0.5)
|
|
Creatinine (mg/dL)
|
0.9 (0.2)
|
1 Some patients may have more than one indication.
Table 2
Findings from EUS.
|
Diagnostic Findings
|
N (%)
|
|
|
20 (23.5)
|
|
|
9 (10.6)
|
|
|
9 (10.6)
|
|
|
12 (14.1)
|
|
|
4 (4.7)
|
|
|
3 (3.5)
|
|
|
2 (2.3)
|
|
|
2 (2.3)
|
|
|
2 (2.3)
|
|
|
2 (2.3)
|
|
|
2 (2.3)
|
|
|
1 (1.2)
|
|
|
1 (1.2)
|
|
Interventions
|
|
|
1 (1.2)
|
|
|
4 (4.7)
|
|
Normal EUS findings
|
16 (18.8)
|
|
General anesthesia
|
12 (13)
|
|
TIVA
|
80 (87)
|
|
Meaningful Impact
|
69 (81.2)
|
Among interventions, EUS-guided rendezvous was done after failed endoscopic retrograde
cholangiopancreatography (ERCP) in one patient (1.2 %) with cholangitis with failed
biliary cannulation after precut papillotomy ([Fig. 1a], [Fig. 1b], and [Fig. 1c]) and EUS-guided cystogastrostomy for pancreatic pseudocyst was done in four patients
(4.7 %) ([Fig. 2a], [Fig. 2b], [Fig. 2c]). In patients with pseudocyst with abdominal pain and fever, transgastric drainage
was performed by placing a LAMS (Hot AXIOS, Boston Scientific, United States) in two
patients and a biflanged metal stent (Niti-S Nagi stent, Korea) in the other two.
After 4 weeks, CT imaging was done to confirm the cyst resolution, and the stent was
removed endoscopically. In 21 patients diagnosed with CBD calculi, ERCP for stone
retrieval was performed in the same session. In 12 patients with cholelithiasis, subsequent
laparoscopic cholecystectomy was performed. Two patients who were diagnosed with GIST
on EUS-guided FNB underwent laparoscopic resection. The endosography images of various
pathologies have been provided in [Fig. 3a–i]. Patients who had mediastinal and abdominal TB, received a four-drug antitubercular
regimen to which all responded well. Patients in whom no organic cause was found were
managed as having functional abdominal pain. FNA for a mediastinal mass in three other
patients was inconclusive. For diagnostic EUS, there were no intraoperative, delayed
post-procedure, or anesthesia-related complications. For interventional procedures,
mild abdominal pain was encountered in three patients who had undergone cystogastrostomy
and they were treated symptomatically with analgesics.
Fig. 1 a–c EUS-guided rendezvous for failed ERCP in a patient with cholangitis.
Fig. 2 a–c EUS-guided cystogastrostomy for pancreatic pseudocyst.
Fig. 3 a Chronic calcific pancreatitis with multiple calculi. b Large gastric GIST. 3c Gallbladder sludge with microlithiasis. d Pseudopapillary tumor of pancreas. e Choledocholithiasis. f Choledocholithiasis. g Mediastinal lymph node with tuberculosis. h Mediastinal tuberculosis. i Mediastinal lymph node biopsy.
Discussion
By retrospectively analyzing patients over 3 years, we studied the utility of EUS
in pediatric patients. EUS proved useful in diagnosis of gastrointestinal and pancreatobiliary
diseases. It also provided vital information on chronic pancreatitis, cholangitis,
mediastinal tuberculosis, and follow-up of patients with pseudocyst. EUS is infrequently
used due to its limited indications in pediatric patients. There have been a handful
of studies looking at utility of EUS in children. EUS has evolved from a diagnostic
modality to a therapeutic interventional procedure. The therapeutic procedures such
as EUS-guided pseudocyst drainage or EUS-guided rendezvous that have been reported
in this study have rarely been reported in previous studies. To the best of our knowledge,
our study represents the second largest case series addressing the feasibility and
the safety of EUS in the pediatric population.
General anesthesia is favored in young children undergoing complex EUS procedures.
Many factors affect the choice of sedation during pediatric EUS procedures, including:
nature and duration of the procedure, the ASA classification of the patient, anticipated
cooperation of the patient, anesthetist comfort and preference, patients age, endosonographer,
and parents [16]. We safely used TIVA for the majority (87 %) of the cases, while GA remains an option.
Most of the studies in the pediatric population have used GA, while some have used
TIVA with propofol. Currently there are no clear-cut guidelines on when to use TIVA
or GA in children undergoing EUS procedures. At our center, we prefer to use TIVA
with propofol as the prime drug, because it has a predictable and rapid recovery profile
with lower incidence of post-operative nausea and vomiting. Glycopyrrolate negates
bradycardia induced by propofol and also serves as an antisialagogue. Lignocaine reduces
the pain associated with propofol intravenous injection, reduces the cough reflex,
and prevents laryngospasm. Nalbuphine is used as an opioid analgesic. However, when
need arises TIVA can be switched over to GA. For children who undergo pseudocyst drainage
and other interventional procedures, it is always advisable to use GA. Pharmacoeconomic
studies on the cost of TIVA vs. GA for EUS in pediatric patients is currently unavailable.
Adult gastroenterologists carry out the majority of EUS procedures in pediatric population.
This trend may continue for some time due to the limited availability of pediatric
gastroenterologists trained in EUS. EUS when done by experts is safe, and has good
clinical outcomes among pediatric patients with low complications, as seen in this
study. MRCP and EUS are radiation-free and very useful in the detection of pancreatobiliary
diseases yielding good diagnostic accuracy. MRCP is safe and noninvasive, but may
require sedation to avoid movement artifacts in young children. CT cannot evaluate
certain pancreatobiliary abnormalities. ERCP has a good diagnostic capability for
biliary pathologies, but the complication rates range from 3.4 % to 28.5 % in children
[17]
[18]. EUS has good sensitivity and specificity for microlithiasis, and choledocholithiasis,
with 33 patients were diagnosed with gallstone or CBD calculi in our study. It can
prevent unnecessary ERCP in pediatric cases. The ASGE guidelines for suspected choledocholithiasis
recommends using a non-invasive test, such as EUS or MRCP, prior to ERCP [19]. In one patient of pancreatic divisum, MRCP was inconclusive but EUS confirmed the
same. In the second patient, EUS showed the presence of pancreatic divisum which was
later confirmed on MRCP before proceeding for endotherapy. Similarly, in patients
in whom cholelithiasis and choledocholithiasis was missed on ultrasound of abdomen,
but correctly diagnosed on EUS have been included for meaningful impact. By utilizing
EUS in patient management, it has had an impact on the clinical management of cases
from 35.5 % to 93 %. The meaningful impact on the subsequent clinical management in
our study was 69(81.2 %) ([Table 3]). All these studies ([Table 4]) suggest that EUS is safe and effective in the pediatric population when performed
by expert endosonographers. EUS is believed to have superior imaging qualities for
pancreatic diseases, especially early diagnosis of CP [20]. The present study findings are similar to those found across the world for early
diagnosis of CP. EUS whenever done carefully and by experts, can be a useful tool
both for detection of CP and monitoring disease progression. Identification of patients
with CP among the acute recurrent pancreatitis cases is useful for counseling on prognosis.
Table 3
Comparison of pre-EUS findings with meaningful impact during EUS.
|
Pre-EUS findings
|
Meaningful impact, n = 69[1]
|
|
Abdominal pain
|
Choledocholithiasis
|
|
Cholelithiasis/gallbladder microlithiasis
|
|
Non-Hodgkin lymphoma
|
|
Chronic pancreatitis
|
|
Pancreatic pseudocyst
|
|
Pseudopapillary tumor of the pancreas
|
|
Jaundice/cholangitis
|
Choledocholithiasis
|
|
Choledochal cyst
|
|
Biliary ascariasis
|
|
Recurrent acute pancreatitis
|
Chronic pancreatitis
|
|
Pancreatic divisum
|
|
Gastrointestinal submucosal lesion
|
Esophageal duplication cyst
|
|
Gastric GIST
|
|
Mediastinal lesion
|
Mediastinal tuberculosis
|
|
Lymphadenopathy
|
Abdominal tuberculosis (lymph nodes)
|
EUS, endoscopic ultrasound; GIST, gastrointestinal stromal tumor.
1 Some patients may have more than one finding.
Table 4
Endoscopic ultrasound in pediatric patients from selected published studies.
|
Authors, year
|
Country
|
Study design, follow-up
|
Patients
|
Procedures
|
Age in years, range
|
Gender
|
Anesthesia N (%)
|
Meaningful impact, %
|
Complications
|
|
Roseau G et al. 1998 [10]
|
France
|
Retrospective 1987–1994
|
18
|
23
|
4–16
|
–
|
DS 100 %
|
–
|
–
|
|
Varadarajulu S et al. 2005 [6]
|
USA
|
Prospective 2001–2004
|
14
|
15
|
5–17
|
M 64 %
|
GA 100 %
|
93
|
–
|
|
Bjerring OS et al. 2008 [9]
|
Denmark
|
Retrospective 1992–2006
|
18
|
18
|
0.5–15
|
M 67 %
|
GA 100 %
|
78
|
–
|
|
Cohen S et al. 2008 [32]
|
Israel
|
Retrospective 1999–2005
|
32
|
32
|
1.5–18
|
M 65 %
|
CS 56 % GA 38 %
|
44
|
–
|
|
Attila T et al. 2009 [8]
|
USA
|
Retrospective 2001–2008
|
38
|
40
|
3–17
|
M 58 %
|
GA 67.5 % DS 22.5 % CS 10 %
|
–
|
–
|
|
Al-Rashdan A et al. 2010 [7]
|
USA
|
Retrospective 2000–2008
|
56
|
58
|
4–18
|
F 62.5 %
|
DS 73 % GA 17 % CS 6 %
|
86
|
–
|
|
Scheers I et al. 2015 [33]
|
Belgium
|
Retrospective 2000–2014
|
48
|
52
|
2–17
|
F 60.4 %
|
GA 86 % DS 14 %
|
98
|
3.8 %
|
|
Jia Y et al. 2015 [34]
|
USA
|
Retrospective 2011–2014
|
5
|
6
|
6–17
|
F 60 %
|
GA 100 %
|
100
|
–
|
|
Mahajan R et al. 2016 [4]
|
India
|
Retrospective 2006–2014
|
121
|
125
|
3–18
|
M 58 %
|
CS 65 % GA 35 %
|
35.5
|
2.4 %
|
|
Fugazza A et al. 2017 [3]
|
Italy
|
Retrospective 2010–2016
|
40
|
47
|
3–18
|
M 55 %
|
DS 48.9 % GA 21.3 %
|
87.2
|
–
|
|
Raina A et al. 2017 [35]
|
USA
|
Retrospective 2007–2012
|
58
|
70
|
6–21
|
M 50 %
|
GA 57 % MAC 29 % MS 14 %
|
88
|
12 %
|
|
Gordon K et al. 2016 [36]
|
USA
|
Retrospective 2005–2012
|
43
|
51
|
4–18
|
F 69.8 %
|
–
|
80
|
2.3 %
|
|
Singh SK et al. 2018 [37]
|
India
|
Prospective 2015–2016
|
32
|
35
|
8–18
|
M68.7 %
|
CS 100 %
|
–
|
–
|
|
Téllez-Ávila et al. 2019 [38]
|
Mexico
|
Retrospective 2009–2016
|
54
|
54
|
9–17
|
F 59.3 %
|
DS 100 %
|
–
|
–
|
|
Altonbary AY et al. 2020 [39]
|
Egypt
|
Retrospective 2016–2020
|
13
|
13
|
6–18
|
F 61.5 %
|
TIVA 100 %
|
77
|
–
|
|
Our study
|
India
|
Retrospective 2018– 2020
|
85
|
92
|
5–18
|
M 70.5 %
|
GA 13 % TIVA 87 %
|
81.2
|
–
|
MS, moderate sedation; MAC, monitored anesthesia care; GA, general anesthesia; CS,
conscious sedation.
Pancreatic pseudocysts were initially drained surgically or percutaneously. Over time,
pancreatic fluid collections are predominantly drained endoscopically, especially
with EUS guidance. Cystogastrostomy in children has got good success rate, as seen
with four of our cases (100 %). It is advisable to utilize endoscopic drainage when
feasible as it has good outcomes [6].
EUS can differentiate gastrointestinal wall layers, thereby helping to identify mucosal/submucosal
lesions [21]. Malignant tumors of the digestive system in children account for about 1% of the
cases [22]. Among gastric tumors seen in the pediatric population are lymphomas and sarcomas.
One child in our study had non-Hodgkin lymphoma and two patients had GIST. The former
was referred to a nearby oncology institute for further management. EUS is commonly
used for drainage of intraabdominal abscesses in children, with a reported improvement
rate of 50 % to 80 % [23]
[24]. The ASGE Technology Committee provides guidance on the EUS equipment for pediatric
endoscopy [25]. For patients weighing < 15 kg, “through‑the scope miniprobes with frequencies ranging
from 12 to 30 MHz may be used through standard gastroscopes with a 2.8‑mm working
channel” [25].
Complications of diagnostic EUS are extremely rare. The risk of pancreatitis has been
described in patients undergoing FNA of pancreatic lesions, with rates ranging from
0.44 % to 2 % [26]
[27]. Bile peritonitis is also a risk unique to EUS. The incidence rate for EUS-related
complications by Mahajan et al. ranged between 1.96 % and 7.1 %, which was reported
in only four studies [4]. Complications included mild pancreatitis after FNA of solid pancreatic lesions,
fever, and bleeding after EUS-guided cystogastrostomy, and anesthesia-related complications
(hypoxia due to airway obstruction and laryngospasm). However, in our case, we did
not encounter any complications.
Of late, there have been some unique pediatric cases that have been successfully managed.
EUS-guided HotAxios was used to treat a traumatic pancreatic pseudocyst in a 12-year-old
child by Ardengh JC et al. in 2020 [28]. EUS-guided pancreatic duct rendezvous was done in a child with traumatic pancreatic
duct disruption [29].
Successful EUS-guided drainage was achieved of an intra-abdominal abscess in a 1-year-old
infant by Ito Y et al. in 2016 [30]. The youngest child known to have undergone EUS was 0.5 months old [31]. All these cases show that EUS can be safely performed in children of all age groups.
However, we feel EUS is not ideal in children younger than age 2 years, in children
with esophageal strictures, and those who have low body weight.
The study does have its limitations. First, it was a single centered retrospective
study with a small sample size and noncomparative design; a larger patient group would
have been ideal for this population. Combining data from multiple centers may overcome
the limitations of a small sample size. Being a tertiary referral center, the study
might have included a selected subset of referred patients; thereby an element of
referral bias might exist, the results of which may not be generalizable outside of
this environment. Retrospective studies can miss major clinical events. There may
be misclassification bias. There may also be an element of selection bias that might
have contributed to the results. But retrospective studies play a major role in health
research, especially when evidence from randomized studies is not available or not
feasible. Nevertheless, the findings from this study add to the current pool of existing
knowledge and provide a reference for future studies in India and across the world.
Conclusions
To summarize, the utility of EUS among the studied pediatric population appears safe
and effective for the diagnosis and treatment of upper gastrointestinal tract disorders.
EUS in our study had a positive meaningful impact on the clinical management of children.
Adequate care should be exercised, especially during therapeutic interventions and
with anesthesia care. The cost implications appear to hinder routine diagnostic use
of EUS and need to be analyzed in well-controlled studies.